Toxicity and inflammatory response in Swiss albino mice after intraperitoneal and oral administration of polyurethane nanoparticles

Toxicology Letters

Volumn 246, Issue , 2016, Pages 17-27

  Silva, Adny H ^a   Locatelli, Claudriana ^b   Filippin Monteiro, Fabíola B ^a   Martin, Philip ^c   Liptrott, Neill J ^c   Zanetti Ramos, Betina G ^d   Benetti, Luana C ^a   Nazari, Evelize M ^a   Albuquerque, Cláudia A C ^a   Pasa, André A ^a   Owen, Andrew ^c   Creczynski Pasa, Tânia B ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b UNIVERSIDADE DO OESTE DE SANTA CATARINA   (Brazil)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d Nanovetores Encapsulados de Alta Tecnologia   (Brazil)

Author keywords

Biocompatibility; In vitro; In vivo; Inflammation; Nanoparticles; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; CHOLESTEROL; CREATININE; GLUCOSE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIVER ENZYME; POLYURETHAN; PROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UREA; NANOPARTICLE;

ADIPOSE TISSUE; ALBINO MOUSE; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; BLOOD CLOTTING TIME; BLOOD FLOW; CELL COUNT; CELL VACUOLE; CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE RELEASE; EX VIVO STUDY; GLUCOSE BLOOD LEVEL; HEMOLYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY INFILTRATE; INTRAABDOMINAL FAT; KIDNEY; LIPID STORAGE; LIVER; LIVER CELL; LIVER FUNCTION; LONG TERM EXPOSURE; LUNG; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; TOXICITY ASSAY; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL; ANIMAL; BLOOD; CHEMICALLY INDUCED; INTRAPERITONEAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; HUMANS; INFLAMMATION; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-6; MALE; MICE; NANOPARTICLES; POLYURETHANES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84956648673     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2016.01.018     Document Type: Article

References (76)

1. Agasti S.S., Rana S., Park M.H., Kim C.K., You C.C., Rotello V.M. Nanoparticles for detection and diagnosis. Adv. Drug Deliv. Rev. 2010, 62:316-328.
2. Bonzani I.C., Adhikari R., Houshyar S., Mayadunne R., Gunatillake P., Stevens M.M. Synthesis of two-component injectable polyurethanes for bone tissue engineering. Biomaterials 2007, 28:423-433.
3. Borm P.J., Robbins D., Haubold S., Kuhlbusch T., Fissan H., Donaldson K., Schins R., Stone V., Kreyling W., Lademann J., Krutmann J., Warheit D., Oberdorster E. The potential risks of nanomaterials: a review carried out for ECETOC. Part. Fibre Toxicol. 2006, 3:1-35.
4. Camner P., Lundborg M., Lastbom L., Gerde P., Gross N., Jarstrand C. Experimental and calculated parameters on particle phagocytosis by alveolar macrophages. J. Appl. Physiol. 2002, 92:2608-2616.
5. Chang H., Ho C.-C., Yang C.S., Chang W.-H., Tsai M.-H., Tsai H.-T., Lin P. Involvement of MyD88 in zinc oxide nanoparticle-induced lung inflammation. Exp. Toxicol. Pathol. 2013, 65:887-896.
6. Chattopadhyay P., Shekunov B.Y., Yim D., Cipolla D., Boyd B., Farr S. Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system. Adv. Drug Deliv. Rev. 2007, 59:444-453.
7. Chen J., Dong X., Zhao J., Tang G. In vivo acute toxicity of titanium dioxide nanoparticles to mice after intraperitioneal injection. J. Appl. Toxicol. 2009, 29:330-337.
8. Cho W.-S., Cho M., Jeong J., Choi M., Cho H.-Y., Han B.S., Kim S.H., Kim H.O., Lim Y.T., Chung B.H., Jeong J. Acute toxicity and pharmacokinetics of 13 nm-sized PEG-coated gold nanoparticles. Toxicol. Appl. Pharmacol. 2009, 236:16-24.
9. Copple B.L., Ganey P.E., Roth R.A. Liver inflammation during monocrotaline hepatotoxicity. Toxicology 2003, 190:155-169.
10. Devanand Venkatasubbu G., Ramasamy S., Ramakrishnan V., Kumar J. Folate targeted PEGylated titanium dioxide nanoparticles as a nanocarrier for targeted paclitaxel drug delivery. Adv. Powder Technol. 2013, 24:947-954.
11. Ding M., He X., Wang Z., Li J., Tan H., Deng H., Fu Q., Gu Q. Cellular uptake of polyurethane nanocarriers mediated by gemini quaternary ammonium. Biomaterials 2011, 32:9515-9524.
12. Dobrovolskaia M.A., Aggarwal P., Hall J.B., McNeil S.E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm. 2008, 5:487-495.
13. Donaldson K., Tran L., Jimenez L.A., Duffin R., Newby D.E., Mills N., MacNee W., Stone V. Combustion-derived nanoparticles: a review of their toxicology following inhalation exposure. Part. Fibre Toxicol. 2005, 2:1-14.
14. Du J., Wang S., You H., Zhao X. Understanding the toxicity of carbon nanotubes in the environment is crucial to the control of nanomaterials in producing and processing and the assessment of health risk for human: a review. Environ. Toxicol. Pharmacol. 2013, 36:451-462.
15. Ehrenberg M.S., Friedman A.E., Finkelstein J.N., Oberdorster G., McGrath J.L. The influence of protein adsorption on nanoparticle association with cultured endothelial cells. Biomaterials 2009, 30:603-610.
16. Elsaesser A., Howard C.V. Toxicology of nanoparticles. Adv. Drug Deliv. Rev. 2012, 64:129-137.
17. Fainboim L., Cherñavsky A., Paladino N., Flores A.C., Arruvito L. Cytokines and chronic liver disease. Cytokine Growth Factor Rev. 2007, 18:143-157.
18. Faraji A.H., Wipf P. Nanoparticles in cellular drug delivery. Bioorg. Med. Chem. 2009, 17:2950-2962.
19. Fleischer C.C., Kumar U., Payne C.K. Cellular binding of anionic nanoparticles is inhibited by serum proteins independent of nanoparticle composition. Biomater. Sci. 2013, 1:975-982.
20. Garg D.K., Goyal R.N. Hematological and hepatotoxic effects of silken styles of corn in albino-rats. J. Appl. Toxicol. 1992, 12:359-363.
21. Ge H., Hu Y., Jiang X., Cheng D., Yuan Y., Bi H., Yang C. Preparation, characterization, and drug release behaviors of drug nimodipine-loaded poly(epsilon-caprolactone)-poly(ethylene oxide)-poly(epsilon-caprolactone) amphiphilic triblock copolymer micelles. J. Pharm. Sci. 2002, 91:1463-1473.
22. Grunkemeier J.M., Tsai W.B., Horbett T.A. Hemocompatibility of treated polystyrene substrates: contact activation, platelet adhesion, and procoagulant activity of adherent platelets. J. Biomed. Mater. Res. 1998, 41:657-670.
23. Hiura T.S., Li N., Kaplan R., Horwitz M., Seagrave J.C., Nel A.E. The role of a mitochondrial pathway in the induction of apoptosis by chemicals extracted from diesel exhaust particles. J. Immunol. 2000, 165:2703-2711.
24. Holpuch A.S., Hummel G.J., Tong M., Seghi G.A., Pei P., Ma P., Mumper R.J., Mallery S.R. Nanoparticles for local drug delivery to the oral mucosa: proof of principle studies. Pharm. Res. 2010, 27:1224-1236.
25. Hussain S., Boland S., Baeza-Squiban A., Hamel R., Thomassen L.C.J., Martens J.A., Billon-Galland M.A., Fleury-Feith J., Moisan F., Pairon J.-C., Marano F. Oxidative stress and proinflammatory effects of carbon black and titanium dioxide nanoparticles: role of particle surface area and internalized amount. Toxicology 2009, 260:142-149.
26. Ilinskaya A.N., Dobrovolskaia M.A. Nanoparticles and the blood coagulation system. Part II: safety concerns. Nanomedicine 2013, 8:969-981.
27. Indulekha K., Anjana R.M., Surendar J., Mohan V. Association of visceral and subcutaneous fat with glucose intolerance, insulin resistance, adipocytokines and inflammatory markers in Asian Indians. Clin. Biochem. 2011, 44:281-287. (CURES-113).
28. Ishida T., Harashima H., Kiwada H. Interactions of liposomes with cells in vitro and in vivo: opsonins and receptors. Curr. Drug Metab. 2001, 2:397-409.
29. Joshi M.D., Müller R.H. Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm. 2009, 71:161-172.
30. Kovačević V., Šmit I., Hace D., Sućeska M., Mudri I., Bravar M. Role of the polyurethane component in the adhesive composition on the hydrolytic stability of the adhesive. Int. J. Adhes. Adhes. 1993, 13:126-136.
31. Koziara J.M., Oh J.J., Akers W.S., Ferraris S.P., Mumper R.J. Blood compatibility of cetyl alcohol/polysorbate-based nanoparticles. Pharm. Res. 2005, 22:1821-1828.
32. Kumari A., Yadav S.K., Yadav S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B: Biointerfaces 2010, 75:1-18.
33. Kwon S.M., Nam H.Y., Nam T., Park K., Lee S., Kim K., Kwon I.C., Kim J., Kang D., Park J.H., Jeong S.Y. In vivo time-dependent gene expression of cationic lipid-based emulsion as a stable and biocompatible non-viral gene carrier. J. Control Release 2008, 128:89-97.
34. Laschke M.W., Strohe A., Scheuer C., Eglin D., Verrier S., Alini M., Pohlemann T., Menger M.D. In vivo biocompatibility and vascularization of biodegradable porous polyurethane scaffolds for tissue engineering. Acta Biomater. 2009, 5:1991-2001.
35. Linkov I., Steevens J., Adlakha-Hutcheon G., Bennett E., Chappell M., Colvin V., Davis J., Davis T., Elder A., Foss Hansen S., Hakkinen P., Hussain S., Karkan D., Korenstein R., Lynch I., Metcalfe C., Ramadan A., Satterstrom F. Emerging methods and tools for environmental risk assessment, decision-making, and policy for nanomaterials: summary of NATO Advanced Research Workshop. J. Nanopart. Res. 2009, 11:513-527.
36. Liptrott N.J., Giardiello M., Hunter J.W., Tatham L., Tidbury L.R., Siccardi M., Rannard S., Owen A. Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions. Nanomedicine 2014, 10:1407-1421.
37. Luque-Garcia J.L., Sanchez-Díaz R., Lopez-Heras I., Camara C., Martin P. Bioanalytical strategies for in-vitro and in-vivo evaluation of the toxicity induced by metallic nanoparticles. TrAC, Trends Anal. Chem. 2013, 43:254-268.
38. Müller R.H., Runge S., Ravelli V., Mehnert W., Thünemann A.F., Souto E.B. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int. J. Pharm. 2006, 317:82-89.
39. McCarron P.A., Donnelly R.F., Canning P.E., McGovern J.G., Jones D.S. Bioadhesive, non-drug-loaded nanoparticles as modulators of candidal adherence to buccal epithelial cells: a potentially novel prophylaxis for candidosis. Biomaterials 2004, 25:2399-2407.
40. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 2001, 53:283-318.
41. Morton, D.B., Jennings, M., Buckwell, A., Ewbank, R., Godfrey, C., Holgate, B., Inglis, I., James, R., Page, C., Sharman, I., Verschoyle, R., Westall, L., Wilson, A.B., 2001. Refining procedures for the administration of substances. Report of the BVAAWF/FRAME/RSPCA/UFAW Joint Working Group on Refinement. British Veterinary Association Animal Welfare Foundation/Fund for the Replacement of Animals in Medical Experiments/Royal Society for the Prevention of Cruelty to Animals/Universities Federation for Animal Welfare. Laboratory animals 35, 1-41.
42. Nagarwal R.C., Kant S., Singh P.N., Maiti P., Pandit J.K. Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J. Control. Release 2009, 136:2-13.
43. Nemmar A., Albarwani S., Beegam S., Yuvaraju P., Yasin J., Attoub S., Ali B.H. Amorphous silica nanoparticles impair vascular homeostasis and induce systemic inflammation. Int. J. Nanomed. 2014, 9:2779-2789.
44. OECD, 2001. OECD Guideline for Testing of Chemicals. http://www.oecd.org/chemicalsafety/testing/oecdguidelinesforthetestingofchemicals.htm.
45. Oberdorster G., Maynard A., Donaldson K., Castranova V., Fitzpatrick J., Ausman K., Carter J., Karn B., Kreyling W., Lai D., Olin S., Monteiro-Riviere N., Warheit D., Yang H. Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy. Part. Fibre Toxicol. 2005, 2:1-35.
46. PEN, 2009. PEN - The Project on Emerging Nanotechnologies. PEN - The Project on Emerging Nanotechnologies, p. http://www.nanotechproject.org/inventories/consumer/.
47. Pacheco P.M., Le B., White D., Sulchek T. Tunable complement activation by particles with variable size and fc density. Nano Life 2013, 3:1-20.
48. Pardeike J., Hommoss A., Müller R.H. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int. J. Pharm. 2009, 366:170-184.
49. Pari L., Murugavel P. Role of diallyl tetrasulfide in ameliorating the cadmium induced biochemical changes in rats. Environ. Toxicol. Pharmacol. 2005, 20:493-500.
50. Park E.-J., Park K. Oxidative stress and pro-inflammatory responses induced by silica nanoparticles in vivo and in vitro. Toxicol. Lett. 2009, 184:18-25.
51. Park E.-J., Bae E., Yi J., Kim Y., Choi K., Lee S.H., Yoon J., Lee B.C., Park K. Repeated-dose toxicity and inflammatory responses in mice by oral administration of silver nanoparticles. Environ. Toxicol. Pharmacol. 2010, 30:162-168.
52. Parveen S., Sahoo S.K. Polymeric nanoparticles for cancer therapy. J. Drug Target. 2008, 16:108-123.
53. Peng Q., Wei X.Q., Shao X.R., Zhang T., Zhang S., Fu N., Cai X.X., Zhang Z.R., Lin Y.F. Nanocomplex based on biocompatible phospholipids and albumin for long-circulation applications. ACS Appl. Mater. Interfaces 2014, 6:13730-13737.
54. Plapied L., Duhem N., des Rieux A., Préat V. Fate of polymeric nanocarriers for oral drug delivery. Curr. Opin. Colloid Interface Sci. 2011, 16:228-237.
55. Pujalté I., Passagne I., Brouillaud B., Tréguer M., Durand E., Ohayon-Courtès C., L'Azou B. Cytotoxicity and oxidative stress induced by different metallic nanoparticles on human kidney cells. Part. Fibre Toxicol. 2011, 8:1-16.
56. Qiu Y., Park K. Environment-sensitive hydrogels for drug delivery. Adv. Drug Deliv. Rev. 2001, 53:321-339.
57. Savolainen K., Alenius H., Norppa H., Pylkkanen L., Tuomi T., Kasper G. Risk assessment of engineered nanomaterials and nanotechnologies-a review. Toxicology 2010, 269:92-104.
58. Shinde S.K., Grampurohit N.D., Gaikwad D.D., Jadhav S.L., Gadhave M.V., Shelke P.K. Toxicity induced by nanoparticles. Asian Pac. J. Trop. Dis. 2012, 2:331-334.
59. Silva A.H., Filippin-Monteiro F.B., Mattei B., Zanetti-Ramos B.G., Creczynski-Pasa T.B. In vitro biocompatibility of solid lipid nanoparticles. Sci. Total Environ. 2012, 432:382-388.
60. Silva A.H., Locatelli C., Filippin-Monteiro F.B., Zanetti-Ramos B.G., Conte A., Creczynski-Pasa T.B. Solid lipid nanoparticles induced hematological changes and inflammatory response in mice. Nanotoxicology 2013, 8:212-219.
61. Singh R., Lillard J.W. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol. 2009, 86:215-223.
62. Su Y., Peng F., Jiang Z., Zhong Y., Lu Y., Jiang X., Huang Q., Fan C., Lee S.-T., He Y. In vivo distribution, pharmacokinetics, and toxicity of aqueous synthesized cadmium-containing quantum dots. Biomaterials 2011, 32:5855-5862.
63. Sun X., Gao H., Wu G., Wang Y., Fan Y., Ma J. Biodegradable and temperature-responsive polyurethanes for adriamycin delivery. Int. J. Pharm. 2011, 412:52-58.
64. Upadhyay D., Panduri V., Ghio A., Kamp D.W. Particulate matter induces alveolar epithelial cell DNA damage and apoptosis: role of free radicals and the mitochondria. Am. J. Respir. Cell Mol. Biol. 2003, 29:180-187.
65. Venkataraman S., Hedrick J.L., Ong Z.Y., Yang C., Ee P.L.R., Hammond P.T., Yang Y.Y. The effects of polymeric nanostructure shape on drug delivery. Adv. Drug Deliv. Rev. 2011, 63:1228-1246.
66. Wang M., Thanou M. Targeting nanoparticles to cancer. Pharmacol. Res. 2010, 62:90-99.
67. Wang Y.X., Robertson J.L., Spillman W.B., Claus R.O. Effects of the chemical structure and the surface properties of polymeric biomaterials on their biocompatibility. Pharm. Res. 2004, 21:1362-1373.
68. Wang J.-J., Liu K.-S., Sung K.C., Tsai C.-Y., Fang J.-Y. Lipid nanoparticles with different oil/fatty ester ratios as carriers of buprenorphine and its prodrugs for injection. Eur. J. Pharm. Sci. 2009, 38:138-146.
69. Wang A., Gao H., Sun Y., Sun Y.-l.Yang Y.-W., Wu G., Wang Y., Fan Y., Ma J. Temperature- and pH-responsive nanoparticles of biocompatible polyurethanes for doxorubicin delivery. Int. J. Pharm. 2013, 441:30-39.
70. Yokel R.A., MacPhail R.C. Engineered nanomaterials: exposures, hazards, and risk prevention. J. Occup. Med. Toxicol. 2011, 6:1-27.
71. You D., Liang H., Mai W., Zeng R., Tu M., Zhao J., Zha Z. Microwave-assisted functionalization of polyurethane surface for improving blood compatibility. J. Ind. Eng. Chem. 2013, 19:1587-1592.
72. Yuan J., Lin S., Shen J. Enhanced blood compatibility of polyurethane functionalized with sulfobetaine. Colloids Surf. B: Biointerfaces 2008, 66:90-95.
73. Zanetti-Ramos B.G., Lemos-Senna E., Soldi V., Borsali R., Cloutet E., Cramail H. Polyurethane nanoparticles from a natural polyol via miniemulsion technique. Polymer 2006, 47:8080-8087.
74. Zhang R., Niu Y., Li Y., Zhao C., Song B., Li Y., Zhou Y. Acute toxicity study of the interaction between titanium dioxide nanoparticles and lead acetate in mice. Environ. Toxicol Pharmacol. 2010, 30:52-60.
75. Zhang X., Sun M., Zheng A., Cao D., Bi Y., Sun J. Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration. Eur. J. Pharm. Sci. 2012, 45:632-638.
76. Zia K.M., Bhatti I.A., Barikani M., Zuber M., Bhatti H.N. XRD studies of polyurethane elastomers based on chitin/1,4-butane diol blends. Carbohydr. Polym. 2009, 76:183-187.